Abstract
The use of brachytherapy for the definitive treatment of localized prostate cancer has been established for over four decades (1). Therapy may be delivered using either permanent seed low dose rate (LDR) or high dose rate (HDR) technique. Both techniques are recommended in the ASCO/CCO joint guidelines (2), and data suggests comparable oncologic outcomes. Brachytherapy may be used as monotherapy for low risk and selected intermediate risk patients or in conjunction with external beam radiation therapy (EBRT) for unfavorable intermediate and high risk patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
